Taysha Gene Therapies Inc (TSHA)
1.24
-0.10
(-7.46%)
USD |
NASDAQ |
Nov 05, 10:28
Taysha Gene Therapies Debt to Equity Ratio: 0.3475 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.3475 |
| March 31, 2024 | 0.7523 |
| December 31, 2023 | 0.5406 |
| September 30, 2023 | -0.7849 |
| Date | Value |
|---|---|
| June 30, 2023 | -1.033 |
| March 31, 2023 | -2.553 |
| December 31, 2022 | 40.01 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-2.553
Minimum
Mar 2023
40.01
Maximum
Dec 2022
5.325
Average
0.3475
Median
Jun 2024
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.4322 |
| IGC Pharma Inc | 0.0173 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Protalix BioTherapeutics Inc | 0.7145 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 200.39M |
| Total Liabilities (Quarterly) | 91.52M |
| Shareholders Equity (Quarterly) | 108.87M |
| Current Ratio | 5.222 |
| Net Debt Paydown Yield | 0.01% |